# Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

> **NCT00837265** · PHASE2,PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 334 (actual)

## Conditions studied

- Chemotherapy-induced Neutropenia

## Interventions

- **BIOLOGICAL:** Balugrastim
- **DRUG:** Pegfilgrastim
- **DRUG:** Chemotherapy Regimen

## Key facts

- **NCT ID:** NCT00837265
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-21
- **Primary completion:** 2009-06-26
- **Final completion:** 2009-06-26
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837265, "Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00837265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*